Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
Holding BNTX?
Track your performance easily
BNTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$76.53 - $131.49
Previous CloseN/A
Volume316.50K
Average Volume (3M)671.31K
Market Cap
$26.95B
Enterprise Value$10.67B
Total Cash (Recent Filing)$172.35M
Total Debt (Recent Filing)$50.35M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Mar 10, 2025EPS Estimate
0.42Last Dividend Ex-Date
Jun 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-2.10
Shares Outstanding237,766,240
10 Day Avg. Volume801,971
30 Day Avg. Volume671,307
Standard Deviation0.22
R-Squared0.00192
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.90
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue3.34
Enterprise Value/Gross Profit3.32
Enterprise Value/Ebitda4.53
Forecast
1Y Price Target
$142.00Price Target Upside25.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
BioNTech SE News
PremiumCompany Announcements
BioNTech Unveils 2025 Strategic Priorities and Pipeline Progress
PremiumCompany Announcements
BioNTech Settles Royalty Dispute with NIH for $791.5 Million
PremiumCompany Announcements
BioNTech Settles Royalty Dispute with University of PennsylvaniaBulls Say, Bears Say
Bulls Say
Clinical Trials And Drug EfficacyBNT327+chemo shows a promising outcome in lower PD-L1 expressers (CPS<10) compared to standard chemotherapy.
Financial Resources And Strategic DevelopmentBNTX has substantial financial resources to fund aggressive development plans for BNT327, which could be critical for realizing its potential.
Product Development And Market PotentialThe oncology pipeline, particularly the BNT327 product, is seen as having a significant revenue potential, with BNT327 being potentially first to market in key indications.
Bears Say
Clinical Trial SetbackA partial clinical hold on the Phase 3 trial of gotistobart in relapsed non-small cell lung cancer raises concerns about BioNTech's development strategy.
Financial PerformanceBioNTech guided to the low end of its €2.5-3.1B revenue range due to pricing pressure and lower demand in middle and low-income countries.
Vaccine Business UncertaintyAn outspoken vaccine skeptic introduces uncertainty to BioNTech’s vaccine business, affecting investor confidence.
---
Ownership Overview
― Insiders
3.63% Mutual Funds
<0.01% Other Institutional Investors
95.38% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BNTX FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $76.53 and its highest was $131.49 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is $26.95B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Mar 10, 2025 which is in 51 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Nov 04, 2024. The company reported $0.835 earnings per share for the quarter, beating the consensus estimate of -$1.581 by $2.415.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE pays a Notavailable dividend of $1.534 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is 0.42.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 237,766,240 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of $0.835 in its last earnings report, beating expectations of -$1.581. Following the earnings report the stock price went down -2.252%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in BNTX
---
BioNTech SE Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$142.00 (25.93% Upside)
$142.00 (25.93% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 646.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $103.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.24%
12-Months-Change
Fundamentals
Return on Equity
-2.37%
Trailing 12-Months
Asset Growth
6.33%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.
---
BNTX Company Deck
---
BNTX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, driven by significant revenue growth, advancements in COVID-19 vaccines, and progress within the oncology pipeline. However, there were concerns regarding increased operating costs and contractual disputes. The financial guidance being at the lower end of the range was a noted challenge.Read More>---
BNTX Stock 12 Month Forecast
Average Price Target
$142.00
▲(25.93% Upside)
Technical Analysis
Moderna
―
Novavax
―
Vaxart
―
Inovio Pharmaceuticals
―
Arcturus Therapeutics
―
GlaxoSmithKline
―
Best Analysts Covering BNTX
1 Year
1 Year Success Rate
7/8 ratings generated profit
1 Year Average Return
+21.60%
reiterated a buy rating 2 months ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +21.60% per trade.
---